Methods and compositions for treating hypertriglyceridemia

US11090310B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• Kazuya Miyashita · Shibukawa, JP
• Stephen G. Young · Chicopee, US
• Anne P. Beigneux · Los Angeles, US
• Loren G. Fong · Los Angeles, US
• Katsuyuki Nakajima · Shibukawa, JP

Key dates

• Filing date: Jul 28, 2017
• Grant date: Aug 17, 2021
• Expiry date: Dec 25, 2037

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/044
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

This application describes novel therapeutic strategies for treating patients with hypertriglyceridemia and/or chylomicronemia based on the presence of GPIHBP1 autoantibodies. It was unexpectedly found that autoantibodies to GPIHBP1, a GPI anchored protein of capillary endothelial cells that shuttles lipoprotein lipase to its site of action in the capillary lumen, were found to be present in patients with hypertriglyceridemia, and that the autoantibodies blocked the binding of lipoprotein lipase (LPL) to GPIHBP1. Patients having hypertriglyceridemia and/or chylomicronemia and also having GPIHBP1 autoantibodies may be treated with a therapeutically effective amount of an immunosuppressive treatment and/or GPIHBP1 activator.